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HIV-1 infection requires the presence of specific chemokine receptors on CD4/ target cells to enable the fusion reactions
involved in virus entry. CCR5 is a major fusion coreceptor for macrophage-tropic HIV-1 isolates. HIV-1 entry and fusion are
mediated by the viral envelope glycoprotein (Env) and are inhibited by CCR5 ligands, but the mechanisms are unknown.
Here, we test the role of G protein signaling and CCR5 surface downmodulation by two separate approaches: direct
inactivation of CCR5 signaling by mutagenesis and inactivation of Gi-type G proteins with pertussis toxin. A CCR5 mutant
lacking the last 45 amino acids of the cytoplasmic C-terminus (CCR5306) was created that was expressed on transfected
cells at levels comparable to cells expressing CCR5 and displayed normal chemokine binding affinity. CCR5 ligands induced
calcium flux and receptor downmodulation in cells expressing CCR5, but not in cells expressing CCR5306 . Nevertheless,
CCR5 or CCR5306 , when coexpressed with CD4, supported comparable HIV-1 Env-mediated cell fusion. Consistent with this,
treatment of CCR5-expressing cells with pertussis toxin completely blocked ligand-induced transient calcium flux, but did
not affect Env-mediated cell fusion or HIV-1 infection. Also, pertussis toxin did not block chemokine inhibition of Env-
mediated cell fusion or HIV-1 infection. However, chemokines inhibited Env-mediated cell fusion less efficiently for CCR5306
than for CCR5. We conclude that the C-terminal domain of CCR5 is critical for G protein signaling and receptor downmodula-
tion from the surface, but that neither function is required for CCR5 fusion coreceptor activity. The contrasting phenotypes
of CCR5 and CCR5306 suggest that coreceptor downmodulation and direct blockage of Env interaction sites both contribute
to chemokine inhibition of HIV-1 infection. q 1997 Academic Press
INTRODUCTION discovery that it is a receptor for the CXC chemokine
stromal cell-derived factor-1 (SDF-1), which blocks TCL-
HIV initiates infection of CD4/ cells by a process of tropic HIV-1 strains (Bleul et al., 1996; Oberlin et al., 1996).
direct fusion between the virion membrane and the target The identification of a CXC chemokine receptor as a
cell membrane. In addition to CD4, the target cell must fusion cofactor for TCL-tropic strains, coupled with an
express additional human-specific cofactors to allow fu- earlier demonstration that certain CC chemokines sup-
sion mediated by HIV-1 Env (Alkhatib et al., 1996a; Ash- press infection by macrophage-tropic HIV-1 strains (Coc-
orn et al., 1990; Broder et al., 1993; Clapham et al., 1991; chi et al., 1995), quickly led to the identification of the
Dragic et al., 1992; Harrington et al., 1993; Maddon et CC chemokine receptor CCR5 (Combadiere et al., 1996;
al., 1986; Nussbaum et al., 1994; Ramarli et al., 1993; Samson et al., 1996) as a fusion cofactor for macrophage-
Weiner et al., 1991). Recent discoveries have revealed tropic HIV-1 strains (Alkhatib et al., 1996b; Choe et al.,
that the fusion cofactors for HIV-1 are specific chemokine 1996; Deng et al., 1996; Doranz et al., 1996; Dragic et al.,
receptors (reviewed in Berger, 1997). The first cofactor 1996). Coreceptor activity has also been reported for the
discovered was a putative G protein-coupled receptor CC chemokine receptors CCR3 and CCR2b (Choe et al.,
(designated ‘‘fusin’’) that was identified by a functional 1996; Doranz et al., 1996) as well as for an ‘‘orphan’’
cDNA cloning strategy focused on the cofactor for T-cell receptor with unknown ligand specificity (Liao et al.,
line-tropic (TCL-tropic) HIV-1 isolates (Feng et al., 1996). 1997). With the recent findings that direct molecular inter-
The protein was subsequently renamed CXCR4 upon the actions occur between the fusion cofactors, Env and
CD4, (Lapham et al., 1996; Trkola et al., 1996; Wu et
al., 1996), it is appropriate to view these molecules as1 These authors contributed equally to the work.
coreceptors.2 Present address: Instituto Richerche Farmacologiche ‘‘Mario Negri,’’
Milano, Italy. The mechanism of action of the coreceptors in the
3 To whom correspondence and reprint requests should be ad- fusion process, and the mode of inhibition by the chemo-
dressed. Edward A. Berger, Bldg 4, Rm 236, NIH, Bethesda, MD 20892.
kine ligands, are poorly understood. Of particular interestFax: (301) 480-1147. E-mail: edward_berger@nih.gov; or Philip M. Mur-
are the possible roles of G protein signal transductionphy, Bldg 10, Rm 11N113, NIH, Bethesda, MD 20892. Fax: (301) 402-
4369, E-mail: pmm@nih.gov. and surface receptor downmodulation in these pro-
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cesses. The present study addresses these questions megalovirus and bacteriophage T7 promoters. The nucle-
otide sequence was confirmed by double-stranded DNAby analysis of fusion under conditions where signaling
is blocked by mutation of the coreceptor or by treatment sequencing using the Sequenase DNA sequencing kit
version 2.0 (USB, Cleveland, OH).with an inhibitor of signal transduction. Our results dem-
onstrate that coreceptor function is independent of G
protein signaling; furthermore they suggest two mecha- Expression of recombinant CCR5 and CCR5306
nisms by which chemokines block the fusion process:
surface receptor downmodulation and direct blocking. Stable cell lines were prepared expressing the recom-
binant chemokine receptors. HEK 293 cells were grown
to log phase in DMEM-10, and 107 cells were electropor-MATERIALS AND METHODS
ated using a GenePulser (Bio-Rad Laboratories, Her-
Cell lines, viruses, and materials cules, CA) with 20 mg of plasmid DNA containing the
appropriate cDNA insert. Colonies resistant to 2 g/L G-Human HeLa, human embryonic kidney HEK 293, and
418 (Gibco BRL) were isolated and expanded in the samemurine fibroblast NIH 3T3 cell lines (American Type Cul-
media supplemented with 2 g/L G-418.ture Collection, Rockville, MD) were cultured in DMEM-
As an alternative method, recombinant chemokine re-10 [Dulbecco’s modified Eagle’s medium (Quality Biologi-
ceptors were produced along with CD4 using the vac-cals, Gaithersburg, MD) containing 10% fetal bovine se-
cinia virus expression system. NIH 3T3 cells were trans-rum (FBS, HyClone, Logan, UT), 2 mM L-glutamine, 100
fected using DOTAP lipofection (Boehringer Mannheim,U/ml penicillin, and 100 mg/ml streptomycin]. The human
Indianapolis, IN) with pcDNA3-based plasmids whichPM1 T-cell line (Lusso et al., 1995) was obtained from
contained cDNAs encoding CCR5 or CCR5306 linked tothe NIH AIDS Research and Reference Reagent Program
the bacteriophage T7 promoter; control cells were trans-(Rockville, MD) and was grown in RPMI-10 [RPMI 1640
fected with the pcDNA3 vector alone. After 4 hr at 377,medium (Quality Biologicals) containing 10% FBS, 10 mM
the cells were coinfected with vTF7-3 encoding T7 RNAHepes, 2 mM glutamine, and antibiotics]. Recombinant
polymerase (Fuerst et al., 1993) and vCB-3 encoding CD4vaccinia virus stocks were prepared by standard proce-
(Broder et al., 1993). In both viruses the foreign genesdures (Earl et al., 1991). Pertussis toxin was obtained
were linked to vaccinia early/late promoters; the multi-from List (Campbell, CA). Recombinant chemokines were
plicity of infection was 10 PFU/cell for each virus. Cellpurchased from Peprotech (Rocky Hill, NJ). Fura 2-AM
cultures were incubated at 317 overnight to allow expres-and propidium iodide were obtained from Molecular
sion of the vaccinia-encoded proteins and then washedProbes (Eugene, OR). Sodium azide and ATP were from
and resuspended.Sigma (St. Louis, MO).
ImmunocytochemistryCCR5 constructs
We created epitope-tagged variants of CCR5 to enable Rabbit polyclonal antisera were raised against a syn-
thetic peptide corresponding to amino acids 1–28 of thedetection by the M5 monoclonal antibody (Kodak, Roch-
ester, NY). We amplified the CCR5 open reading frame wild-type CCR5 sequence conjugated to KLH. HEK 293
cells were detached by incubation in PBS at 377 for 15from the clone 8.5 cDNA (Combadiere et al., 1996) by
PCR using the following primers: (1) for full-length CCR5 min, washed twice in flow cytometry buffer (HBSS supple-
mented with 0.5% FBS and 0.02% sodium azide), and(designated CCR5): a 3*-oligonucleotide containing (from
3* to 5*) 27 bases complementary to the last 9 codons resuspended in 100 ml flow cytometry buffer at 107/ml.
Cells were then incubated with a 1:50 dilution of rabbitof CCR5, 3 bases for the stop codon, 6 bases for an XhoI
restriction site, and 8 miscellaneous bases; (2) for CCR5 antisera at 47 for 30 min. They were then washed twice,
resuspended in 100 ml ice-cold flow cytometry buffer inlacking most of the cytoplasmic C-terminus (designated
CCR5306): a 3*-oligonucleotide containing (from 3* to 5*) the presence of FITC-conjugated anti-rabbit IgG (Sigma)
and incubated at 47 for 30 min. Finally, cells were washed27 bases complementary to codons 298–306 of CCR5,
3 bases for a stop codon, 6 bases for an XhoI restriction twice, resuspended in 500 ml ice-cold flow cytometry
buffer containing propidium iodide and analyzed in asite, and 8 miscellaneous bases; and (3) for both con-
structs: a 5*-oligonucleotide containing (from 5* to 3*) 8 FACScan cytometer (Beckton–Dickinson). Alternatively,
cells were suspended in a 1:1 (vol:vol) mixture of 2.5%miscellaneous bases, 6 bases for a HindIII site, 3 bases
for the start codon, 24 bases encoding the flag epitope E-MEM and PBS containing 0.1% BSA. Each sample was
incubated with rabbit antiserum at a 1:50 dilution forDYKDDDDK, and 27 bases complementary to CCR5 co-
dons 2 to 10. The resulting two PCR products were di- 45 min at room temperature. Subsequently, cells were
washed with PBS and incubated with a 1:10 dilution ofgested and subcloned between the HindIII and XhoI sites
of the mammalian expression vector pcDNA3 (Invitrogen, FITC-conjugated F(ab*)2 goat anti-rabbit IgG (Boehringer
Mannheim) for 30 min at room temperature.San Diego, CA); this vector contains both human cyto-
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Ligand binding assay activity produced in response to cell fusion was quanti-
tated by colorimetric assay of detergent cell lysates. To
NIH 3T3 cells (2 1 106) expressing vaccinia-encoded analyze the effects of chemokines on cell fusion activity,
CCR5 or CCR5306 (and CD4) were incubated in triplicate chemokines were added individually or in combination
with 0.25 nM 125I-labeled MIP-1a (sp act 2200 Ci/mmol, to the target cells expressing CCR5 or CCR5306 , and incu-
DuPont NEN) plus varying concentrations of unlabeled bated for 1 hr at 377 before mixing with Env-expressing
recombinant human MIP-1a (Peprotech, Rocky Hill, NJ) HeLa cells. In some experiments, the stably transfected
in 20 ml of binding buffer (HBSS with 1 mg/ml bovine HEK 293 cell lines, or the transiently transfected NIH 3T3
serum albumin plus sodium azide, pH 7.4). After 1 hr cells, were incubated for 3 hr at 377 with pertussis toxin
incubation at room temperature cells were washed with prior to infection with vaccinia viruses. The cells were
binding buffer containing 0.5 M sodium chloride, and cell then incubated overnight at 317 in the presence of pertus-




PM1 cells were preincubated for 1.5 hr at 377 in the
Receptor activation was assessed by real time mea- presence or absence of RANTES and pertussis toxin.
surement of [Ca2/]i changes using a MSIII fluorimeter Cell-free HIV-1 Ba-L was added and the mixtures were
(Photon Technology International, S. Brunswick, NJ) in distributed to multiple wells of 96-well microtiter plates
HEK 293 cell lines expressing receptor constructs as (1 1 105 cells/well) and incubated at 377. The following
previously described (Combadiere et al., 1996). Briefly, day, 50-ml aliquots of cell suspension were collected;
cells were loaded with 2 mM FURA-2AM at 377 for 45 every 3–4 days thereafter, 100-ml aliquots of cell suspen-
min, washed twice, and resuspended at 106 cells/ml in sion were removed and replaced with fresh medium con-
HBSS, pH 7.4. Two milliliters of the cell suspension were taining the same agents. Samples were assayed for p24
placed in a stirred, water-jacketed cuvette at 377, and content by enzyme-linked immunosorbent assay (Du-
excited sequentially at 340 and 380 nm. Fluorescence pont).
emission was monitored at 510 nm before and after addi-
tion of agonists. For some experiments, cells were incu-
RESULTS
bated with 250 ng/ml pertussis toxin for 3 hr prior to
functional assay. Signaling by G protein-coupled receptors is thought to
involve conformational changes of the intracellular do-
Cell fusion assay mains induced by ligand binding (Lefkowitz, 1993;
Strader et al., 1994). As one approach to assess the
Fusion between effector cells expressing HIV-1 Env importance of G protein signaling in CCR5’s function as
and target cells expressing CD4 was quantitated by a an HIV-1 coreceptor, we examined a mutant form of
vaccinia-based reporter gene assay in which b-galactos- CCR5 truncated at amino acid 306, designated CCR5306 .
idase is produced selectively in fused cells (Nussbaum This receptor variant lacks almost the entire predicted
et al., 1994). As effector cells, HeLa cells were coinfected cytoplasmic C-terminal segment. The corresponding do-
with vCB-21R, which encodes the Escherichia coli LacZ main has been shown previously to be a determinant of
gene under control of the bacteriophage T7 promoter signaling for several related 7 transmembrane domain
(Alkhatib et al., 1996a), and a recombinant vaccinia virus chemoattractant receptors, including the chemokine re-
encoding one of the following HIV-1 Envs (Broder and ceptors CXCR2 and CCR2b (Ben-Baruch et al., 1995;
Berger, 1995): M-tropic Envs Ba-L (vCB-43; note this is a Franci et al., 1996). Previously, we have shown that stimu-
correction of the nomenclature used for this virus in lation of cells expressing CCR5 with its ligands MIP-1a,
Broder and Berger, 1995), ADA (vCB-39), SF-162 (vCB- MIP-1b, or RANTES induces a calcium flux response that
32), and JR-FL (vCB-28); and Unc, an uncleavable mutant can be completely blocked by pretreatment of the cells
of IIIB (vCB-16). In one protocol, the target cells were the with pertussis toxin (Combadiere et al., 1996), suggesting
HEK 293 cell transfectants stably expressing the indi- coupling to Gi-type G proteins (Simon et al., 1991). There-
cated CCR5 contructs. These cells were coinfected with fore, to further assess the role of signaling we also exam-
vCB-3 encoding human CD4 and vTF7-3 encoding T7 ined the effects of pertussis toxin on the HIV-1 coreceptor
RNA polymerase. In another protocol, the targets were activity of CCR5.
NIH 3T3 cells coexpressing vaccinia-encoded CD4, the
indicated CCR5 constructs, and T7 RNA polymerase. Du- The C-terminal domain of CCR5 is not required for
plicate samples of 105 Env-expressing effector cells and cell surface expression or chemokine binding
105 CD4//coreceptor/ target cells were mixed in 96-well
microtiter plates in the presence of cytosine arabinoside Cell surface expression of CCR5 and CCR5306 was
analyzed by flow cytometry using as the probe either a(40 mg/ml) and incubated at 377 for 2 hr. b-galactosidase
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surface expression. Similar results were obtained in
analyses of CCR5 and CCR5306 produced transiently us-
ing the vaccinia expression system (see below). These
results with CCR5 are consistent with those reported for
other chemoattractant receptors (Ben-Baruch et al., 1995;
Murphy, 1996).
We also examined the effects of removal of the C-
terminal domain of CCR5 on binding of chemokine li-
gands. As shown in Fig. 1B, both CCR5 and CCR5306
bound radioinodinated MIP-1a; moreover, the IC50 for
inhibition by unlabeled MIP-1a was equivalent for both
molecules (3 nM). We conclude that the cytoplasmic
C-terminal domain of CCR5 is not required for high affin-
ity ligand binding.
Loss of G protein signaling by truncation of the CCR5
C-terminus
We next tested whether CCR5306 could support ago-
nist-dependent calcium flux responses. This G protein-
dependent response is characteristic of chemokine re-
ceptor activation, is highly associated with other chemo-FIG. 1. Cytoplasmic C-terminal domain of CCR5 is not required for
kine-induced cell responses, and is a convenient way ofcell surface expression or ligand binding. (A) Surface expression. HEK
293 transfectant cell lines stably expressing CCR5, CCR5306 , or CCR2b monitoring receptor activation in real time using calcium-
were stained with a polyclonal rabbit antiserum raised against amino sensitive dyes such as Fura-2, which can be loaded into
acids 1-28 of CCR5, and analyzed by flow cytometry. ‘‘None’’ refers to living cells (Grynkiewicz et al., 1985). The HEK 293
parental HEK 293 cells. Expression of CCR2b was verified by strong
transfectant expressing CCR5 exhibited a robust re-calcium flux responses induced by MCP-1 and MCP-3 (not shown),
sponse to the CCR5 ligand RANTES, whereas a RANTES-consistent with our previous report (Combadiere et al., 1995). (B) Ligand
binding. NIH 3T3 cells expressing vaccinia-encoded CD4 and CCR5 induced response was not detectable in the transfectant
(open circles) or CCR5306 (closed circles) were incubated with 0.25 nM expressing CCR5306 (Fig. 2). The same dichotomy was
125I-labeled MIP-1a alone, or in the presence of increasing concentra- observed when the other CCR5 ligands, MIP-1a and MIP-
tions of unlabeled MIP-1a. Receptor-positive cells represented 12% of
1b, were tested (not shown). As controls, the cells ex-the population for each construct, as assessed by flow cytometry using
pressing CCR5 and CCR5306 exhibited similar responsesthe rabbit polyclonal antiserum directed against CCR5. Cells trans-
fected with the control vector gave a low background of binding that to ATP (Fig. 2), which activates an endogenous signaling
was not competed by cold MIP-1a (open squares). All values are the pathway in HEK 293 cells (probably mediated by P2 pu-
average of triplicate determinations {SD. rinergic receptors). We have also confirmed our previous
reported result that the calcium flux response mediated
by CCR5 can be completely blocked by pertussis toxin
rabbit polyclonal antiserum generated against a syn-
(Combadiere et al., 1996 and data not shown). Taken
thetic peptide representing the predicted extracellular
together, the results presented so far indicate that the
amino terminal domain of CCR5 (amino acids 1–28) or
C-terminal segment of CCR5 beyond amino acid 306 con-
a mAb recognizing the Flag epitope. Figure 1A shows
tains determinants critical for signal transduction, proba-
analysis of HEK 293 cells stably transfected with various
bly by mediating interaction with Gi-type G proteins.chemokine receptor constructs. Specific cell surface
staining at comparable intensity was obtained when cells CCR5 signaling through G proteins is not required for
stably transfected with either CCR5 or CCR5306 were in- HIV-1 coreceptor activity
cubated with the anti-CCR5 antiserum. In contrast, cells
stably transfected with the closely related receptor The results presented above provided an opportunity
to test whether G protein signaling is required for theCCR2b (75% amino acid identity) gave only background
fluorescence equivalent to that observed with the paren- HIV-1 coreceptor activity of CCR5. We used a quantitative
vaccinia-based reporter gene assay of HIV-1 Env-medi-tal HEK 293 cells. With preimmune serum, only low back-
ground staining was observed with all cell lines (not ated cell fusion (Nussbaum et al., 1994). HEK 293 cell
transfectants expressing CCR5 or CCR5306 (along withshown). Staining with the anti-Flag mAb gave concordant
results (not shown). We conclude that the rabbit antise- vaccinia-encoded CD4) were tested for their ability to
fuse with HeLa cells expressing vaccinia-encoded Envsrum is specific for the CCR5 amino terminus, that this
domain is exposed extracellularly, and that the intracellu- from several M-tropic strains. As shown in Fig. 3, compa-
rable levels of fusion occurred with CCR5 and CCR5306lar C-terminal domain is not required for efficient cell
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tion by the M-tropic Ba-L isolate. We extended these anal-
yses to cells expressing recombinant CCR5. As shown in
Fig. 5, fusion of Env-expressing cells with HEK 293 CCR5
transfectant cells coexpressing vaccinia-encoded CD4
was unaffected by 500 ng/ml pertussis toxin. Similar re-
sults documented no effect of pertussis toxin on cell fusion
when CCR5 was expressed (along with CD4) using the
vaccinia expression system (data not shown). Thus, per-
tussis toxin at concentrations that potently block G protein-
mediated signal transduction had minimal effect on either
Env-mediated cell fusion or productive infection. These
results parallel earlier reports that pertussis toxin did not
block entry/infection by TCL-tropic (Orloff et al., 1991) or
M-tropic (Cocchi et al., 1996) strains.
Chemokine inhibition of fusion coreceptor activity
does not require G protein signaling or the C-terminal
domain of CCR5
RANTES, MIP-1a, and MIP-1b suppress productive
HIV-1 infection (Cocchi et al., 1995) by inhibiting CCR5-
FIG. 2. The C-terminal domain of CCR5 is a major determinant of G
protein signaling. Relative fluorescence was monitored in CCR5- and
CCR5306-expressing HEK 293 transfectant cell lines loaded with Fura
2 (top and bottom panels, respectively), before and during sequential
stimulation with 50 nM RANTES and 50 nM ATP at the times indicated
by the arrows. The tracings shown are from the same experiment,
which is representative of greater than ten separate experiments using
at least five separate clones for each receptor. In each case, similar
expression levels of CCR5 and CCR5306 were verified by staining with
the anti-CCR5 rabbit antiserum.
for each Env tested. Similar results were obtained in an
alternative protocol whereby CCR5 and CCR5306 were
coexpressed with CD4 on NIH 3T3 cells using the tran-
sient vaccinia expression system (not shown). Thus, the
C-terminal truncation that abolished the G protein signal
transduction activity of CCR5 had no effect on fusion
coreceptor activity.
Pertussis toxin provided an alternative means to test
the requirement for G protein signal transduction in the
fusion coreceptor activity of CCR5. The experiment shown
in Fig. 4 was performed with the Jurkat-derived T-cell line
PM1 as the target. PM1 cells express CD4 and are highly
susceptible to M-tropic HIV-1 strains (Lusso et al., 1995).
Moreover, CCR5 mRNA is expressed in these cells (Alk-
hatib et al., unpublished data), and infection by M-tropic
isolates is potently inhibited by CCR5 ligands, suggesting
that the major native coreceptor for M-tropic HIV-1 on PM1
cells is CCR5 (Cocchi et al., 1996; Oravecz et al., 1996). FIG. 3. The cytoplasmic C-terminal domain of CCR5 is dispensable
When PM1 cells were used as target cells in the cell for HIV-1 coreceptor activity. CCR5- and CCR5306-expressing HEK 293
transfectant cell lines also expressing vaccinia-encoded CD4 werefusion assay with effector HeLa cells expressing the
tested for their ability to fuse with HeLa cells expressing the indicatedBa-L Env, the efficient fusion observed was completely
HIV-1 Envs. Cell fusion was measured by quantitation of b-galactosi-resistant to 500 ng/ml pertussis toxin (Fig. 4A). We also
dase activity in cell lysates. The results are the mean{ SEM of a single
tested the effects of pertussis toxin on productive HIV-1 experiment representative of at least five independent experiments.
infection of PM1 cells (Fig. 4B). In the continuous presence Background fusion activity, defined using HeLa cells expressing the
Unc Env as effectors, was consistently below 5 in all experiments.of pertussis toxin (500 ng/ml), we observed robust infec-
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transfectants expressing either CCR5 or the signaling-
incompetent truncation mutant CCR5306 (along with CD4,
Fig. 6A). Similar effects were seen when the coreceptors
and CD4 were expressed on NIH 3T3 cells using the
vaccinia system: RANTES, MIP-1a, and MIP-1b each in-
hibited Env-mediated fusion with both CCR5 and CCR5306
(Fig. 6B). We consistently observed that fusion inhibition
was less efficient with the CCR5306 variant compared to
CCR5, as shown by the higher concentrations required
for an equivalent percentage of inhibition (Fig. 6A) and
the less extensive inhibition observed at high concentra-
tions of each chemokine (Fig. 6B). These findings, cou-
pled with the results presented in the following section,
have important implications for the mechanisms of chem-
okine inhibition of HIV-1 entry (see Discussion).
The C-terminus of CCR5 is essential for surface
downmodulation by chemokines
Binding of ligands to G protein-coupled receptors in
general, and chemokine receptors in particular, often re-
sults in reduced cell surface expression of the receptor
(Sabroe et al., 1997), a process known as receptor se-
questration or downmodulation. This process is thoughtFIG. 4. Blockade of G protein signaling by pertussis toxin does not
affect CCR5 coreceptor activity or chemokine inhibition of coreceptor to explain in part the phenomenon of receptor desensiti-
activity in the PM1 T-cell line. (A) Cell fusion. Target PM1 cells were zation (Lefkowitz, 1993) and could be important either for
mixed with effector HeLa cells expressing the HIV-1 Envs Unc or Ba-L, HIV-1 Env-dependent membrane fusion and/or chemo-in the presence of the indicated combinations of 500 ng/ml pertussis
kine inhibition of fusion. Figure 7 shows that CCR5 wastoxin (PT) and 500 nM RANTES (R). Cell fusion was measured by quanti-
strongly downmodulated by chemokine ligands, whereastation of b-galactosidase activity in cell lysates. Results are the mean
{ SEM from a single experiment representative of three independent the truncated CCR5306 receptor was unaffected. Thus, in
experiments. (B) Productive HIV infection. PM1 cells were infected with addition to containing critical determinants of signaling,
HIV-1 Ba-L in the presence of the indicated combinations of 500 ng/ the C-terminal domain of CCR5 also contains essentialml pertussis toxin and 500 nM RANTES. Cell-free supernatants were
determinants for chemokine-mediated downmodulation.analyzed for p24 content.
Further study will be required to learn whether CCR5
downmodulation is obligatorily linked to G protein signal-
ing and whether the C-terminal domain determinants thatdependent Env-mediated membrane fusion and virus en-
support each function are the same or different.try (Alkhatib et al., 1996b; Choe et al., 1996; Deng et al.,
1996; Doranz et al., 1996; Dragic et al., 1996). We wished
to test the role of G protein signal transduction in this
process and again used pertussis toxin and CCR5306 as
probes. With PM1 cells expressing endogenous CCR5,
pertussis toxin did not impair the blocking effects of
RANTES on cell fusion with the Ba-L Env (Fig. 4A) or
productive infection with the Ba-L strain of HIV-1 (Fig.
5B). These results parallel and extend previous reports
by other laboratories studying native coreceptors on PM1
cells (Cocchi et al., 1996; also stated in Oravecz et al.,
1996 with no data shown). Similarly with cells expressing
recombinant CCR5, pertussis toxin had little effect on the FIG. 5. Blockade of G protein signaling by pertussis toxin does not
ability of RANTES to inhibit cell fusion with the HEK 293 affect chemokine inhibition of CCR5’s HIV-1 coreceptor activity. Target
CCR5-expressing HEK 293 transfectant cells coexpressing vaccinia-CCR5 transformant (Fig. 5) or with NIH 3T3 cells express-
encoded CD4 were mixed with effector HeLa cells expressing the HIV-ing vaccinia-encoded CCR5 (data not shown).
1 Envs Unc or Ba-L in the presence of the indicated combinations ofWe also examined the effects of chemokines on Env-
500 ng/ml pertussis toxin (PT) and 500 nM RANTES (R). Cell fusion
mediated fusion in cells expressing the C-terminal-trun- was measured by quantitation of b-galactosidase activity in cell lysates.
cated variant of CCR5. RANTES inhibited Env-mediated Results are the mean { SEM from a single experiment representative
of three independent experiments.fusion in a dose-dependent fashion in HEK 293 cell
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FIG. 6. Less efficient chemokine inhibition of HIV-1 coreceptor activity with CCR5 lacking the cytoplasmic C-terminal domain. Target cells
expressing CD4 plus the indicated chemokine receptors were preincubated with the designated chemokines and then mixed with effector HeLa
cells expressing the Ba-L Env. Cell fusion was measured by quantitation of b-galactosidase activity in cell lysates. Results are the mean { SEM
from a single experiment. (A) The HEK 293 transformant cell lines were preincubated with various concentrations of RANTES. (B) NIH 3T3 cells
expressing vaccinia-encoded CD4 and CCR5 or CCR5306 were preincubated with MIP-1a (a), MIP-1b (b), RANTES (R), all three chemokines (abR),
or no chemokines (0). Each chemokine was tested individually at 500 nM or together at 170 nM each. Similar expression levels of CCR5 and
CCR5306 was verified by flow cytometry with the anti-CCR5 rabbit antiserum.
DISCUSSION tent with a previous report that removal of the cyto-
plasmic C-terminus of the CXC chemokine receptor
The results presented in this paper demonstrate that
CXCR2 has no effect on ligand binding affinity (Ben-Bar-
G protein signaling is not absolutely required for chemo-
uch et al., 1995). In this respect, our results go beyond
kine inhibition of Env-mediated cell fusion or HIV-1 infec-
a recent study of CCR5/CCR2b chimeric receptors, one
tion. Moreover, they demonstrate that the absence of
of which displayed HIV-1 coreceptor activity but did not
signaling by the truncated receptor CCR5306 is not associ- signal in response to chemokines (Atchison et al., 1996);
ated with altered binding of chemokine ligands, consis-
the significance of this finding was unclear in view of
the fact that extracellular regions of the receptors were
exchanged, and no data on chemokine interaction were
presented. Very recently, Farzan et al. described three
CCR5 point mutants (D76N, D125N/R126N, and R126N)
that had a similar phenotype as our truncated receptor
(lack of MIP-1beta-induced calcium flux activity; intact
HIV-1 coreceptor activity) (Farzan et al., 1997).
Our data do not exclude the possibility that alternative
signaling pathways may be involved in the fusion pro-
cess or its inhibition by chemokines. In particular, the
pertussis toxin data must be viewed in the context of
recent findings that some chemokine receptors are capa-
ble of interacting with pertussis toxin-insensitive G pro-
teins, at least when overexpressed together in heterolo-
gous cell types (Kuang et al., 1996). However, the ability
of pertussis toxin to completely block calcium flux in
response to chemokine activation of CCR5 (Combadiere
et al., 1996) suggests that pertussis toxin-insensitive G
proteins are either not available or not used by CCR5 in
HEK 293 cells; alternatively they may be used but not
FIG. 7. Role of the cytoplasmic C-terminal domain of CCR5 in ligand-
coupled to a calcium mobilizing pathway.induced surface downmodulation. Flow cytometry analysis of surface
Ligand-induced downmodulation of surface CCR5 rep-expression of vaccinia-encoded CCR5 (top and middle panels) and
CCR5306 (bottom panel) on NIH 3T3 cells, preincubated at 377 for 30 min resents an obvious mechanism by which chemokines
in the presence (/) or absence (0) of a mixture of MIP-1a, MIP-1b and inhibit fusion/infection. However, the ability of chemo-
RANTES (170 nM each). The top panel indicates cells stained with either kines to inhibit fusion even when downmodulation is pre-
the polyclonal antiserum (Anti-CCR5) or the preimmune serum from the
vented (i.e., with CCR5306) suggests a second mecha-same rabbit; the middle and bottom panels indicate cells stained with
nism: a direct blocking effect. In view of our finding thatthe anti-CCR5 polyclonal rabbit antiserum. The analysis shown was per-
formed in parallel with the fusion experiment shown in Fig. 6B. truncation of the C-terminus of CCR5 prevents chemo-
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Broder, C. C., and Berger, E. A. (1995). Fusogenic selectivity of the enve-kine-induced downmodulation and reduces the effi-
lope glycoprotein is a major determinant of human immunodeficiencyciency of chemokine inhibition of coreceptor activity, it
virus type 1 tropism for CD4/ T-cell lines vs. primary macrophages.
is likely that both surface downmodulation and direct Proc. Natl. Acad. Sci. USA 92, 9004–9008.
blocking contribute to the inhibitory effects. Both mecha- Broder, C. C., Dimitrov, D. S., Blumenthal, R., and Berger, E. A. (1993).
The block to HIV-1 envelope glycoprotein-mediated membrane fu-nisms therefore must be taken into account in mechanis-
sion in animal cells expressing human CD4 can be overcome by atic interpretations of chemokine inhibition experiments.
human cell component(s). Virology 193, 483–491.These considerations also have implications for design-
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu,
ing novel chemokine receptor-targeted therapies for HIV- L., Mackay, C. R., LaRosa, G., Newman, W., Gerard, N., Gerard, C.,
1, since they suggest that an agent capable of both down- and Sodroski, J. (1996). The b-chemokine receptors CCR3 and CCR5
facilitate infection by primary HIV-1 isolates. Cell 85, 1135–1148.modulating CCR5 and physically blocking its interaction
Clapham, P. R., Blanc, D., and Weiss, R. A. (1991). Specific cell surfacewith Env may be most efficacious.
requirements for the infection of CD4-positive cells by human immu-Our data, suggesting a direct blocking mechanism, are
nodeficiency virus types 1 and 2 and by simian immunodeficiency
consistent with recent studies demonstrating physical virus. Virology 181, 703–715.
interactions between Env, coreceptors, and CD4 (La- Cocchi, F., DeVico, A. L., Garzino-demo, A., Arya, S. K., Gallo, R. C., and
Lusso, P. (1995). Identification of RANTES, MIP-1a, and MIP-1b aspham et al., 1996; Trkola et al., 1996; Wu et al., 1996). A
the major HIV-suppressive factors produced by CD8(/) T cells. Sci-favored model envisions multiple, probably sequential,
ence 270, 1811–1815.interactions whereby gp120 binds first to CD4, then to
Cocchi, F., DeVico, A. L., Garzino-Demo, A., Cara, A., Gallo, R. C., and
the fusion coreceptors; ultimately it is presumed that the Lusso, P. (1996). The V3 domain of the HIV-1 gp120 envelope glyco-
cryptic hydrophobic ‘‘fusion peptide’’ at the N-terminus of protein is critical for chemokine-mediated blockade of infection. Na-
ture Med. 2, 1244–1247.gp41 is exposed so that it can interact with the target
Combadiere, C., Ahuja, S. K., Tiffany, H. L., and Murphy, P. M. (1996).cell membrane to promote the fusion event. Despite the
Cloning and functional expression of CC CKR5, a human monocytenoninvolvement of G protein signaling in fusion, it is inter-
CC chemokine receptor selective for MIP-1a, MIP-b and RANTES.
esting to speculate that Env interactions with coreceptors J. Leuk. Biol. 60, 147–152.
(CCR5, CXCR4, etc.) might trigger signaling processes Combadiere, C., Ahuja, S. K., Van Damme, J., Tiffany, H. L., Gao, J.-L.,
and Murphy, P. M. (1995). Monocyte chemoattractant protein-3 is aunrelated to entry that contribute to the pathogenic se-
functional ligand for CC chemokine receptors 1 and 2b. J. Biol. Chem.quelae associated with HIV infection.
270, 29671–29675.
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